News
PRPH
5.42
+2.07%
0.11
Weekly Report: what happened at PRPH last week (0429-0503)?
Weekly Report · 3h ago
Weekly Report: what happened at PRPH last week (0422-0426)?
Weekly Report · 04/29 09:57
Weekly Report: what happened at PRPH last week (0415-0419)?
Weekly Report · 04/22 09:53
ProPhase Labs Shares Jump on New AI-Based Project
Shares of ProPhase Labs are up 17%, at $7.18, in late trading. The stock is now up 59% since the start of the year. The company unveiled a new project that uses an artificial-intelligence platform and its massive genomics database. ProPhase will use the project to identify new cancer therapeutics.
Dow Jones · 04/16 19:46
ProPhase Labs Unveils Project ZenQ-AI; Leveraging ProPhase Labs' AI Platform, Massive Genomics Database And Patented Esophageal Cancer Insights For Antibody Drug Conjugates Development
Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Project ZenQ-AI uses the Company's state-of-the-art AI platform to identify possible antibody drug conjugate candidates for new cancer therapies. The Company is harnessing its massive genomic database from whole genome sequencing.
Benzinga · 04/16 12:15
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
NASDAQ · 04/15 11:47
Weekly Report: what happened at PRPH last week (0408-0412)?
Weekly Report · 04/15 09:49
ProPhase Labs Seeks To Transform Esophageal Cancer Detection And Management With Launch Of Its BE-Smart Test In H2 2024
ProPhase Labs, Inc. Is aiming for commercial launch of its breakthrough BE-Smart test for esophageal cancer in the second half of 2024. The BE- smart test is a patent-protected method for identifying cancer markers. The test targets an initial market size of $7 billion to $14 billion. The Company is nearing completion of rigorous validation studies of the test.
Benzinga · 04/10 12:09
PROPHASE LABS INC - AIMING FOR COMMERCIAL LAUNCH OF BE-SMART TEST FOR ESOPHAGEAL CANCER IN SECOND HALF OF 2024
Reuters · 04/10 12:03
Weekly Report: what happened at PRPH last week (0401-0405)?
Weekly Report · 04/08 09:51
PROPHASE LABS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/02 01:00
Weekly Report: what happened at PRPH last week (0325-0329)?
Weekly Report · 04/01 09:51
Weekly Report: what happened at PRPH last week (0318-0322)?
Weekly Report · 03/25 09:52
Weekly Report: what happened at PRPH last week (0311-0315)?
Weekly Report · 03/18 09:51
PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q4 2023
ProPhase Labs reported earnings per share of -51 cents. The company reported revenue of $4.35 million. This was 59.30% below the analyst estimate for the company to report revenue of  $10.69 million. The company also reported lower than expected earnings.
Investorplace · 03/15 16:53
ProPhase Labs Q4 EPS $(0.51) Misses $(0.26) Estimate, Sales $4.35M Miss $10.69M Estimate
ProPhase Labs reports quarterly losses of $0.51 per share. The company reported quarterly sales of $4.35 million. ProPhase Labs missed the analyst consensus estimate of $10.69 million by 59.30%. The company also missed the quarterly sales estimate by 80.06%.
Benzinga · 03/15 12:10
*ProPhase Labs 2023 Loss/Shr $0.98 >PRPH
Dow Jones · 03/15 12:02
ProPhase Labs GAAP EPS of -$0.98 misses by $0.24, revenue of $45.2M misses by $6.38M
Seeking Alpha · 03/15 12:01
*ProPhase Labs 2023 Rev $45.2M >PRPH
Dow Jones · 03/15 12:01
BRIEF-ProPhase Labs FY Adjusted EBITDA USD -10.558 Million
Reuters · 03/15 12:00
More
Webull provides a variety of real-time PRPH stock news. You can receive the latest news about Prophase Labs Inc through multiple platforms. This information may help you make smarter investment decisions.
About PRPH
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.